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ABSTRACT
Objectives: We investigated the association between continuous antipsy-
chotic use and health-related quality of life (HRQL) 3-year change in the
European Schizophrenia Outpatients Health Outcomes (EU-SOHO)
study.
Methods: EU-SOHO is an observational study of outcomes associated
with antipsychotic treatment for schizophrenia in an outpatient setting.
HRQL was assessed at study entry and at 6, 12, 18, 24, 30, and 36 months
using the EuroQol-5D (EQ-5D). UK population time trade-off (TTO)
tariffs were applied to the self-rated EQ-5D health states to calculate
HRQL ratings (0 = death, 1 = best). An epoch analysis approach was used
as a conceptual framework to analyze the longitudinal data. Follow-up
was divided into epochs or periods of continuous treatment. When a
patient changed antipsychotic treatment, he or she was considered to
have a new observation. Multilevel models were employed to evaluate
the association of HRQL with medication and other clinical and
sociodemographic variables for each epoch. A total of 9340 patients were
analyzed (42.1% women; mean age 40 years).
Results: Mean EQ-5D scores increased over time; the largest improve-
ment occurred in the ﬁrst 6 months (mean increase of 0.19). Longer
duration of illness and older age at ﬁrst treatment were associated with
worse baseline EQ-5D scores. Improvements in EQ-5D scores were greater
for more socially active patients or those in paid employment. Few
signiﬁcant differences were found between antipsychotic medications.
Olanzapine and clozapine were associated with higher HRQL increases.
Conclusions: Continuous antipsychotic treatment is associated with
important HRQL beneﬁts at 3 years, most of which occurs during the ﬁrst
6 months. Although some medications are associated with better HRQL
outcomes, differences are small.
Keywords: antipsychotics, health-related quality of life, outpatients,
schizophrenia.
Introduction
Treatment of schizophrenia with antipsychotic medication aims
to improve not only the symptoms of illness but also the patient’s
health-related quality of life (HRQL). New antipsychotic medi-
cations have been shown to improve clinical outcomes in the
short term, both in clinical trials [1] and in observational studies
[2]. Studies have analyzed the impact of antipsychotic treatment
on HRQL, but the follow-up periods have been at most 1 year
[3–9]. There is a lack of data on long-term effects of antipsy-
chotic treatment on HRQL. Importantly, changes in HRQL asso-
ciated with treatment could take longer to occur than clinical
changes, or may be linked to the impact of clinical changes on
social functioning, with HRQL improving as a consequence of
both factors. Nevertheless, there is also an ongoing debate on
whether stable patients with schizophrenia who have good
symptom control would have a better HRQL if they were not
maintained on continuous long-term antipsychotics [10].
HRQL is complex and inﬂuenced by many social, psycho-
logical, and clinical factors, including the patient’s age and sex,
insight into illness, severity of current symptoms, and side effects
of medications [11]. HRQL is not a simple measure of response
to treatment but captures the impact of multiple relevant factors
in a single global subjective judgment. HRQL measures have
been applied in naturalistic settings and in clinical trials, but only
the former setting characterizes the broader range of patients
seen in everyday clinical practice. Because proﬁles of HRQL are
reported by patients, not their clinicians, they are of interest to
purchasers and providers of psychiatric services.
A major problem in studying HRQL outcomes in response
to antipsychotic treatment in observational studies is that
patients with schizophrenia frequently change, or discontinue,
their antipsychotic medication [12]. As a result, it is difﬁcult to
attribute changes in outcome to exposure to a particular drug
[13] or relate differences in outcome solely to the pharmacologi-
cal agents. Attributing improvements in clinical and HRQL out-
comes to speciﬁc drug treatments requires analytic procedures
which ensure that treatment intensity, duration, treatment
history, and pretreatment prognostic factors are simultaneously
taken into account. Hierarchical modeling of physician-related
factors must also be included because patients receiving treat-
ment from the same psychiatrist may experience similar out-
comes due to factors such as treatment (optimal prescribing),
insights developed into their illness, and the clinical relationship
between patient and physician (therapeutic alliance). A number
of methodological approaches can be applied to begin to address
these complex issues, but how to do these effectively or optimally
is still a matter of debate. Moreover, the results of observational
studies have to be interpreted with caution because the observed
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outcome differences may be inﬂuenced by unmeasured confound-
ing variables or selection to treatment effects [14,15]. Recent
methodological developments may allow investigators to better
control for biases present in observational studies [16].
The objectives of the present article were to describe the
evolution of HRQL over a period of 3 years in outpatients with
schizophrenia who initiated or changed to a new antipsychotic
treatment at study entry, and to analyze the association between
antipsychotic use and HRQL change within each period of con-
tinuous treatment, so that the effect of consecutive treatment
periods (continuous treatment) could be explored. The European
Schizophrenia Outpatients Health Outcomes (SOHO) study pro-
vided the context and all relevant data for the analyses.
Methods
Study Design and Selection Criteria
The SOHO study is a 3-year longitudinal, observational study,
conducted in 10 European countries (Denmark, France,
Germany, Greece, Ireland, Italy, The Netherlands, Portugal,
Spain, and the United Kingdom), of health outcomes associated
with the treatment of schizophrenia. Ethical approval was
obtained in all countries, either at the site, regional, or national
level, depending on the country and local regulations.
All patients gave at least oral informed consent, and written
informed consent was obtained in Denmark, Italy, Ireland, Por-
tugal, Spain, and the United Kingdom. Details of the rationale
and design of the SOHO study have been provided elsewhere
[17], as have the clinical results at 6, 12, and 36 months [18–20].
Recruitment. A total of 1096 participating psychiatrists enrolled
10,218 patients with schizophrenia who met the following entry
criteria: initiating or changing antipsychotic medication for the
treatment of schizophrenia, presenting within the normal course
of care in the outpatient setting or in the hospital when admission
was planned for the initiation of antipsychotic medication and
discharge was planned within 2 weeks, aged at least 18 years,
and not participating in an intervention study. Patients were
included regardless of the reason for treatment change (e.g., lack
of response, side effects, etc.) and regardless of whether an antip-
sychotic drug was being initiated as a replacement for a previous
medication, whether it was an addition to existing treatment, or
whether it was being initiated for the ﬁrst time or after a period
of no treatment. This was carried out to render the study broadly
representative of schizophrenia outpatients. The recruitment
period lasted from September 1, 2000 to December 31, 2001,
and data collection ﬁnished in January 31, 2005.
Cohorts. Through a stratiﬁed inclusion procedure that over-
sampled patients starting olanzapine, the study was designed to
yield two patient cohorts of approximately equal size: 1) patients
who initiated therapy with, or changed to, olanzapine; and
2) patients who initiated therapy with, or changed to, a non-
olanzapine antipsychotic. Patients in the non-olanzapine cohort
could be prescribed any medication chosen by the psychiatrist.
The current analyses were restricted to those treatment groups
with at least 100 patients initiating that antipsychotic at baseline
and were as follows: olanzapine, risperidone, quetiapine, amisul-
pride, clozapine, oral typical antipsychotics, and depot typical
antipsychotics. Patients who initiated two or more antipsychot-
ics simultaneously were excluded from the analysis (N = 268)
because the study was not intended to address the outcome of
such joint prescribing/polypharmacy, and only a small fraction of
the total sample received such prescriptions.
Enrolment. In most countries, enrollment was conducted in
a systematic alternating order; e.g., such that the ﬁrst patient
was recruited into the olanzapine cohort, the second patient was
recruited into the non–olanzapine cohort, and so on. Effort was
made to avoid interference with normal clinical practice. Inves-
tigators were instructed to make treatment decisions independent
of the study and then evaluate whether patients were eligible for
inclusion based on the entry criteria and the alternating structure
of enrollment. The enrollment period was purposely very long,
and no minimum number of cases was required. All patient care
during the study period was at the discretion of the participating
psychiatrist because SOHO is a naturalistic observational study.
In other words, they could prescribe and change medication at
any time according to their usual clinical practice. No instruc-
tions about patient care were included in the study description.
Data collection for the study occurred during visits that were
within the normal course of health care. The routine outpatient
visit at which patients were enrolled in the study served as the
time for baseline data collection. Subsequent data collection was
targeted for 3, 6, 12, 18, 24, 30, and 36 months postbaseline.
Outcome: Quality of Life
HRQL was assessed using the EuroQol-5D (EQ-5D), a patient
self-rated, generic, HRQL instrument that consists of two parts
[21]: 1) a series of descriptive questions on general health cover-
ing the ﬁve health dimensions of mobility, self-care, usual activi-
ties, pain/discomfort, and anxiety/depression; and 2) a visual
analog scale (VAS) that patients use to assess their current level of
health on the day of scoring from 0 (worst imaginable health
state) to 100 (best imaginable health state). The present study
reports HRQL ratings using the former as it is more comprehen-
sive. HRQL ratings for the self-rated EQ-5D health states were
assigned using the readily available UK population tariffs
(1 = best possible health; 0 = death) [22]. However, HRQL
ratings using EQ-5D VAS were also analyzed. These gave similar
results that are available upon request.
Other measures. Other information collected included: sociode-
mographic variables (age, gender, country, employment, housing,
and number of social activities) and clinical variables [baseline
clinical global impression (CGI) score, whether the patients had
ever received antipsychotic treatment for schizophrenia, age at
ﬁrst treatment contact, previous antipsychotic use, presence of
extra-pyramidal symptoms, presence of tardive dyskinesia, CGI
(positive, negative, depressive, cognitive) symptoms, body mass
index at baseline, alcohol dependence, current substance abuse,
previous hostile behavior, previous suicide attempts, previous
compulsory admission or arrest, taking concomitant medication
at baseline and antipsychotic medication].
Statistical Analysis
Mean [and standard deviations (SD)] EQ-5D tariff scores are
presented for each time point to describe the evolution of the
HRQL. EQ-5D scores are also presented according to the base-
line characteristics of the patients, recorded at study entry.
Because the HRQL data are non-normally distributed (even after
transformations are applied), nonparametric tests, such as the
Wilcoxon signed-rank test, were used for simple group compari-
sons. Hierarchical linear regression models were used to model
changes in HRQL because due to the large sample size and in the
presence of covariates, this method improved assumptions about
the normality of residuals and improved the robustness of the
inferences about associations despite the distributional violations
[23].
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A total of 9340 patients with complete EQ-5D tariff infor-
mation (91.4% of the total at study entry) were included in the
analyses presented here.
Epoch analysis of the longitudinal data. As is characteristic of
schizophrenic patients [24], 42% of the patients in the SOHO
study had either stopped or switched their baseline medication by
36 months. Difﬁculties arise with conventional methods of allo-
cating and interpreting treatment effects on HRQL when patients
frequently switch medication like this. With an intention-to-treat
analysis approach, the recommended method of analyzing ran-
domized controlled trials, the treatment effects are attributed
to the medication given at study entry. When patients frequently
change medication, however, this type of analysis could favor
less-effective medications given at study entry if the patients
subsequently switched to more effective medications. A method
of analysis was thus needed to fully attribute the treatment effects
on HRQL directly to the antipsychotic medication taken by the
patients. An epoch analysis was developed and carried out;
the full methodological details of which have been published
elsewhere [25].
In essence, the 36-month follow-up period of the SOHO data
set was considered as a series of six periods or epochs (0–6, 6–12,
12–18, 18–24, 24–30 or 30–36 months). The ﬁrst 6 months of
any new drug treatment initiated at any time during follow-up
was considered the ﬁrst epoch. If the same drug treatment was
continued for another 6 months, then it would contribute data
for the second epoch. Subsequent epochs were formed if the same
drug treatment was continued for further 6-month intervals in
a consecutive fashion. For instance, if a patient maintained the
medication started at baseline for 24 months and then switched
to a new medication that was maintained for another 12 months,
he/she would have contributed to the analysis, with observations
up to 24 months for the ﬁrst medication (i.e., for the ﬁrst four
epochs each) and observations up to 12 months for the second
medication (i.e., for the ﬁrst two epochs each).
This epoch approach was possible because patients entering
the SOHO study were those who initiated or switched to a new
antipsychotic at baseline. That is, the study is essentially studying
a “window” in the patients’ treatment. If the patient’s medica-
tion was changed during the follow-up, then it was possible to
consider their new treatment as a new observation equivalent
to that at study entry. Thus, patients who changed medication
during follow-up contributed to more than one treatment
episode, with one treatment episode for each new medication
started. This approach thus made the best use of the available
data and took into account the longitudinal structure of the data,
especially, antipsychotic-treatment switching, which is often due
to the experience of a poor outcome. This is captured by includ-
ing all the relevant health-status variables as covariates in the
new epoch (i.e., they are “updated” from study baseline).
Multivariate analyses. Six regression analyses were conducted,
one for each follow-up period of continuous treatment. Each
regression analysis assessed the factors associated with the
change in HRQL at the end of the period. The covariates
included in the model were HRQL, the clinical characteristics of
the patient at the beginning of the period, the baseline clinical
characteristics of the patient, and the medication taken during
the period. A mixed modelling approach was used to take
into account the multilevel and hierarchical nature of the data.
Models included a random intercept at the investigator
level (N = 985 investigators). Effects of country were addressed
through a set of dummy variables, with Germany as the reference
country. For the models with repeated observations per patient, a
random intercept at the patient level was also included to take
into account the lack of independence of longitudinal repeated
measures [26]. A similar approach has been described elsewhere
and applied for cost-effectiveness and cost-utility analyses [27].
Results
Of the 9340 patients assessed at study entry in the present
analysis, the majority (58.1%) were evaluated at all subsequent
study time points (Table 1). At study entry, patient mean age was
40 years (SD 13) and 42.1% were female. Mean duration of
schizophrenia was 11.3 years (SD 11.0), and almost half of the
sample (44.6%) reported having schizophrenia for at least 10
years. Most patients had their ﬁrst contact with the health
services for treatment of schizophrenia before the age of 35 years.
Disease severity at study entry (as assessed using the CGI) was
moderately severe (CGI = 4 in 36.7% patients) to severe (CGI =
5 in 35.2% patients). Table 1 summarizes the social and clinical
characteristics of patients evaluated at all visits and other
patients with some missing data. The groups were similar in
terms of the characteristics measured. The baseline patient char-
acteristics were also similar for the group of patients who com-
pleted the 36-month study (i.e., completers) and the group who
dropped out at any time during follow-up (i.e., noncompleters)
(data available in supplementary information, through ISPOR
ViH supporting information).
Table 2 summarizes the unadjusted EQ-5D tariff scores at
study entry (baseline) and after 6 to 36 months for the total study
sample and by patient characteristics. For the total study sample,
baseline mean and median EQ-5D scores were 0.57 (SD 0.32)
and 0.69, respectively. At baseline, there was a signiﬁcant differ-
ence in the mean EQ-5D score according to CGI severity, ranging
from 0.37 (SD 0.37) for patients with a CGI of 6 to 7, to 0.83
(SD 0.19) for those with a CGI score of 1 to 2 (P < 0.0001).
Baseline mean EQ-5D scores increased signiﬁcantly with an
increasing number of social activities, from 0.48 (SD 0.35)
among those with no social activities to 0.66 (SD 0.28) among
those with ﬁve or more social activities during the past month
(P < 0.0001). In addition, patients with paid employment had a
signiﬁcantly higher baseline mean EQ-5D score compared with
those without paid employment; 0.64 (SD 0.30) versus 0.55 (SD
0.32), (P < 0.0001).
Mean unadjusted EQ-5D scores increased from 0.57 (SD
0.32) at baseline to 0.80 (SD 0.25) after 36 months (Table 2).
The increase in EQ-5D score was greatest after the ﬁrst 6 months
(mean increase of 0.19 for the total study sample). The increase
in EQ-5D score was similar for most of the entry variables
considered. An exception was found for the illness severity vari-
able. Patients with the most severe disease (i.e., highest CGI
score) at study entry had the greatest improvement in HRQL;
mean EQ-5D score increased from 0.37 (SD 0.37) at study entry
to 0.73 (SD 0.33) after 36 months (P < 0.0001). Nevetheless,
those with the lowest (best) CGI score at entry achieved only
little improvement: from 0.83 (SD 0.19) at study entry to 0.86
(SD 0.19) after 36 months (P = 0.006).
Factors Associated with HRQL Change: Results from
Hierarchical, Conditional Models
Multivariate analyses were performed to take into account rel-
evant covariates at study entry as well as at the start of each new
period of continued treatment. Table 3 summarizes the estimates
for the change in EQ-5D tariff score between the speciﬁed levels
of each variable for each of the six epochs.
Duration of illness and age at ﬁrst treatment contact were
consistently associated with the change in EQ-5D score across all
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epoch durations when all other relevant covariates were held
constant. Patients, having suffered from illness for more than
20 years, achieved 0.089 less change in EQ-5D score after
36-months continuous treatment compared with those having
illness for less than 1 year. Similarly, patients who were older
than 35 years at ﬁrst contact for treatment had 0.056 less change
in EQ-5D during 36-months continuous treatment compared
with those who made the ﬁrst contact for treatment when they
were younger than 20 years old. In addition, having paid employ-
ment and having social activities were also associated with a
greater change in EQ-5D (i.e., greater improvement) for most
epoch durations. There were few differences in HRQL score
changes between medication groups. Change in EQ-5D score
was not signiﬁcantly different between patients on olanzapine,
amisulpride, and clozapine, but it was slightly lower for patients
in all other treatment groups compared with the olanzapine
group (Table 3). For example, patients taking olanzapine showed
statistically signiﬁcant greater improvements in EQ-5D score
than patients taking oral typicals for the six epochs (-0.077,
-0.078, -0.064, -0.072, -0.070, and -0.085, respectively).
Figure 1 presents the adjusted mean change (95% conﬁdence
interval) in EQ-5D tariff score after continuous treatment for 6 to
36 months according to duration of illness, baseline clinical
severity, and baseline HRQL. Figure 1C shows that the 25% of
schizophrenia patients with the worst HRQL at baseline [quartile
(Q) 1, according to the EQ-5D score] experienced the largest
improvement in their HRQL, while the 25% of patients with the
best initial HRQL scores (Q4) did not experience any improve-
ments throughout the whole epochs. In addition, the 25% of
patients with second best initial HRQL scores (Q3) also experi-
enced improvements only at the last two epochs (30 and 36
months of continuous treatment).
Discussion
The present study has shown that antipsychotic treatment over
a 36-month period is associated with substantial and sustained
improvement in HRQL in outpatients with schizophrenia. The
mean EQ-5D tariff score increased from 0.57 at study entry to
0.80 after 36 months, reaching a level very close to that of
Table 1 Characteristics of the SOHO study sample at study entry, according to follow-up status
Total
N (%)
9340 (100)*
1 to 4 visits
N (%)
1645 (17.6)
5 to 7 visits
N (%)
2272 (24.3)
All visits
N (%)
5423 (58.1)
Gender
Male 5364 (57.9) 943 (57.8) 1311 (58.3) 3110 (57.7)
Female 3906 (42.1) 689 (42.2) 937 (41.7) 2280 (42.3)
Age at ﬁrst contact (years)
<20 1959 (22.2) 320 (20.9) 493 (23.0) 1146 (22.2)
20 to 25 2254 (25.5) 367 (24.0) 502 (23.4) 1385 (26.8)
25 to 30 1719 (19.4) 271 (17.7) 457 (21.3) 991 (19.2)
30 to 35 1065 (12.0) 196 (12.8) 226 (10.5) 643 (12.4)
35+ 1848 (20.9) 376 (24.6) 469 (21.8) 1003 (19.4)
Duration of illness (years)
Less than 1 1820 (21.0) 449 (30.1) 419 (20.1) 952 (18.7)
1 to 5 1581 (18.2) 294 (19.7) 392 (18.8) 895 (17.6)
5 to 10 1397 (16.1) 220 (14.8) 355 (17.1) 822 (16.1)
10 to 20 2065 (23.8) 283 (19.0) 495 (23.8) 1287 (25.3)
20+ 1804 (20.8) 245 (16.4) 420 (20.2) 1139 (22.4)
First episode
Yes 982 (10.5) 234 (14.2) 221 (9.8) 527 (9.7)
No 8337 (89.5) 1409 (85.8) 2044 (90.2) 4884 (90.3)
CGI score
1 to 2, normal/minimally ill 299 (3.2) 64 (3.9) 69 (3.0) 166 (3.1)
3, mildly ill 1222 (13.1) 213 (13.0) 306 (13.5) 703 (13.0)
4, moderately ill 3417 (36.7) 564 (34.4) 816 (36.0) 2037 (37.6)
5, markedly ill 3282 (35.2) 559 (34.1) 782 (34.5) 1941 (35.9)
6 to 7, severely/most severely ill 1098 (11.8) 238 (14.5) 295 (13.0) 565 (10.4)
Paid employment
Yes 1832 (19.7) 340 (20.8) 426 (18.9) 1066 (19.8)
No 7452 (80.3) 1296 (79.2) 1831 (81.1) 4325 (80.2)
Independent residence
Yes 4543 (48.7) 884 (53.8) 1113 (49.1) 2546 (47.0)
No 4780 (51.3) 758 (46.2) 1153 (50.9) 2869 (53.0)
Number of social activities during the past month
0 3001 (32.5) 552 (34.1) 807 (35.8) 1642 (30,7)
1 to 4 4559 (49.4) 748 (46.3) 1058 (46.9) 2753 (51.4)
5+ 1667 (18.1) 317 (19.6) 391 (17.3) 959 (17.9)
Having a spouse or a partner
Yes 2717 (30.0) 517 (32.5) 670 (30.6) 1530 (29.1)
No 6328 (70.0) 1075 (67.5) 1518 (69.4) 3735 (70.9)
Treatment initiated at entry
Olanzapine 5068 (54.3) 930 (56.5) 1210 (53.3) 2928 (54.0)
Clozapine 306 (3.3) 26 (1.6) 90 (4.0) 190 (3.5)
Risperidone 1806 (19.3) 302 (18.4) 434 (19.1) 1070 (19.7)
Quetiapine 733 (7.9) 132 (8.0) 196 (8.6) 405 (7.5)
Amisulpride 307 (3.3) 77 (4.7) 68 (3.0) 162 (3.0)
Oral typical 660 (7.1) 112 (6.8) 165 (7.3) 383 (7.1)
Depot typical 460 (4.9) 66 (4.0) 109 (4.8) 285 (5.3)
*There are missing values for some categories, so totals do not add up to 9340 for some variables.
CGI, clinical global impression; SOHO, Schizophrenia Outpatients Health Outcomes.
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general European populations which range from 0.74 in Spain
to 0.86 in the United Kingdom [28]. The improvements in
EQ-5D tariff scores were higher during the ﬁrst 6 months of
treatment after study entry. However, these improvements were
not homogenous for all the patients. For example, patients with
the best initial HRQL scores did not experience improvements
throughout continuous treatment. In addition, those with the
second best initial HRQL scores only experienced improve-
ments after 30 months of continuous treatment. This ﬁnding
could partly be explained by regression to the mean of outcome
scores for patients who were initially less ill. Shorter duration of
illness and earlier age at ﬁrst contact with health services were
associated with better HRQL outcomes, as were being in paid
employment or being more socially active at study entry. There
were few differences in HRQL change among medication
cohorts, but with this large sample size, we were able to detect
statistically signiﬁcant differences between olanzapine and the
other medications (except clozapine and amisulpride), although
the clinical signiﬁcance of these differences may be marginal to
moderate. However, the observational design limitations make
it difﬁcult to attribute outcome differences to individual drugs.
Nevertheless, the sensitivity of our results to a range of such
factors has been explored elsewhere and the conclusions altered
very little [12]. Overall, the results are consistent with previous
studies of shorter duration, showing an important, continued
improvement in HRQL associated with continuous therapy over
36 months.
The SOHO study is a large, naturalistic, international, long-
term follow-up study with a high retention rate. Moreover, the
patients lost to follow-up were not substantially different from
those retained in the study on the criteria available to us. The
most important validity threat for SOHO is the consideration
of medication changes and the lack of account taken of time-
varying medication adherence (although most SOHO patients
were highly adherent). Because patients change treatment during
the follow-up, it would be unrealistic to assume that observed
outcomes at follow-up are the consequence of initial treatment
assignment. In most cases, a new treatment is indicated due to
relapse, side effects, or failure to improve symptoms. It would be
inappropriate to assign the outcomes to a previous treatment that
had failed. The method used in the present analysis took into
account medication changes.
The 36-month results presented here are consistent with
the shorter term data from randomized studies [9,29,30] which
describe an important increase in HRQL after antipsychotic
treatment. Moreover, long-term quality-of-life beneﬁts of new
antipsychotics have been reported recently; ziprasidone-treated
patients had a better quality of life than haloperidol-treated
Table 2 EQ-5D tariff score in the SOHO study by follow-up point, according to study entry characteristics
Baseline
N = 9340
6 months
N = 8374
12 months
N = 7974
18 months
N = 7454
24 months
N = 6991
30 months
N = 6566
36 months
N = 6317
Total mean 0.57 (0.32) 0.76 (0.26) 0.78 (0.25) 0.78 (0.26) 0.79 (0.25) 0.80 (0.25) 0.80 (0.25)
Total median (IQ range) 0.69 (0.50) 0.81 (0.31) 0.82 (0.29) 0.85 (0.29) 0.85 (0.29) 0.85 (0.29) 0.85 (0.27)
Gender
Male 0.59 (0.31) 0.77 (0.25) 0.79 (0.24) 0.79 (0.25) 0.80 (0.24) 0.80 (0.24) 0.80 (0.25)
Female 0.54 (0.33) 0.75 (0.27) 0.76 (0.27) 0.77 (0.26) 0.77 (0.27) 0.79 (0.26) 0.80 (0.25)
Age at ﬁrst contact (years)
<20 0.56 (0.33) 0.75 (0.26) 0.76 (0.26) 0.77 (0.26) 0.78 (0.26) 0.79 (0.25) 0.80 (0.25)
20 to 25 0.58 (0.31) 0.77 (0.24) 0.79 (0.23) 0.80 (0.23) 0.81 (0.23) 0.81 (0.23) 0.81 (0.23)
25 to 30 0.57 (0.32) 0.77 (0.25) 0.78 (0.24) 0.79 (0.25) 0.80 (0.25) 0.81 (0.25) 0.81 (0.25)
30 to 35 0.58 (0.56) 0.78 (0.25) 0.79 (0.24) 0.80 (0.24) 0.79 (0.25) 0.81 (0.23) 0.82 (0.24)
35+ 0.56 (0.33) 0.74 (0.28) 0.76 (0.27) 0.76 (0.27) 0.77 (0.28) 0.77 (0.27) 0.78 (0.26)
Duration of illness (years)
Less than 1 0.57 (0.31) 0.79 (0.23) 0.80 (0.23) 0.81 (0.24) 0.82 (0.23) 0.82 (0.23) 0.84 (0.22)
1 to 5 0.60 (0.31) 0.80 (0.24) 0.82 (0.21) 0.83 (0.21) 0.83 (0.22) 0.84 (0.20) 0.84 (0.21)
5 to 10 0.57 (0.31) 0.78 (0.24) 0.79 (0.24) 0.80 (0.24) 0.80 (0.24) 0.81 (0.24) 0.81 (0.24)
10 to 20 0.57 (0.32) 0.75 (0.26) 0.77 (0.25) 0.78 (0.26) 0.79 (0.25) 0.80 (0.25) 0.81 (0.24)
20+ 0.52 (0.34) 0.69 (0.29) 0.71 (0.29) 0.72 (0.29) 0.72 (0.29) 0.73 (0.28) 0.73 (0.29)
First episode
Yes 0.57 (0.32) 0.76 (0.26) 0.77 (0.25) 0.78 (0.26) 0.78 (0.26) 0.79 (0.25) 0.80 (0.25)
No 0.55 (0.31) 0.80 (0.22) 0.81 (0.24) 0.82 (0.23) 0.84 (0.21) 0.84 (0.21) 0.85 (0.20)
CGI score
1 to 2, normal/minimally ill 0.83 (0.19) 0.85 (0.21) 0.87 (0.18) 0.87 (0.18) 0.86 (0.19) 0.87 (0.17) 0.86 (0.19)
3, mildly ill 0.75 (0.22) 0.84 (0.20) 0.85 (0.20) 0.84 (0.21) 0.84 (0.21) 0.85 (0.21) 0.85 (0.20)
4, moderately ill 0.62 (0.28) 0.79 (0.22) 0.79 (0.23) 0.80 (0.23) 0.80 (0.23) 0.81 (0.24) 0.82 (0.22)
5, markedly ill 0.49 (0.33) 0.73 (0.27) 0.75 (0.26) 0.76 (0.26) 0.77 (0.26) 0.78 (0.25) 0.78 (0.26)
6 to 7, severely/most severely ill 0.37 (0.37) 0.66 (0.32) 0.67 (0.32) 0.69 (0.33) 0.72 (0.31) 0.72 (0.32) 0.73 (0.33)
Paid employment
Yes 0.64 (0.30) 0.83 (0.21) 0.84 (0.21) 0.84 (0.22) 0.85 (0.21) 0.86 (0.20) 0.87 (0.20)
No 0.55 (0.32) 0.74 (0.26) 0.76 (0.26) 0.77 (0.26) 0.77 (0.26) 0.78 (0.25) 0.79 (0.26)
Independent residence
Yes 0.59 (0.31) 0.78 (0.25) 0.78 (0.25) 0.79 (0.25) 0.81 (0.25) 0.81 (0.24) 0.82 (0.24)
No 0.55 (0.33) 0.75 (0.26) 0.77 (0.26) 0.77 (0.26) 0.78 (0.26) 0.79 (0.26) 0.79 (0.26)
Number of social activities during the past month
0 0.48 (0.35) 0.71 (0.29) 0.72 (0.29) 0.74 (0.29) 0.74 (0.29) 0.75 (0.29) 0.75 (0.29)
1 to 4 0.59 (0.30) 0.78 (0.24) 0.79 (0.23) 0.80 (0.24) 0.80 (0.23) 0.81 (0.23) 0.83 (0.22)
5+ 0.66 (0.28) 0.81 (0.22) 0.82 (0.21) 0.82 (0.22) 0.83 (0.22) 0.83 (0.22) 0.83 (0.23)
Spouse or partner
Yes 0.56 (0.32) 0.76 (0.26) 0.78 (0.26) 0.78 (0.26) 0.80 (0.25) 0.80 (0.25) 0.81 (0.25)
No 0.57 (0.32) 0.76 (0.25) 0.77 (0.25) 0.78 (0.25) 0.79 (0.25) 0.79 (0.25) 0.80 (0.25)
Data are unadjusted and values are expressed as mean (standard deviation) unless otherwise indicated.
CGI, clinical global impression; EQ-5D, EuroQol-5D; IQ, interquartile; SOHO, Schizophrenia Outpatients Health Outcomes.
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patients during the 3-year double-blind extension phase of a
40-week randomized, double-blind study in patients with schizo-
phrenia [31]. Our observation of greater improvement in HRQL
with olanzapine and clozapine treatment compared with other
antipsychotic medications is consistent with some previous
studies [1,5,30,32–34] but not all [5,35]. One long-term natural-
istic study also demonstrated an increase in HRQL for patients
switching from conventional to novel or atypical antipsychotics
[2]. Nevertheless, several recent studies found that atypical antip-
sychotics produced no greater improvement in quality of life
compared to typical antipsychotics [36,37]. Furthermore, a large
naturalistic study of Canadian patients with schizophrenia found
that the improvement in quality of life over 2 years was not
inﬂuenced by the type of medication prescribed [38]. Although
there are differences in the design and main outcome variables of
these studies, we have ruled out the possibility that our own
observations are biased due to switching antipsychotic treatment.
Thus, maintained improvement in HRQL is attributable to the
treatments studied.
Some limitations of the study deserve discussion. First, due to
the design of the study, half of the patients who were selected
were starting olanzapine, rendering this a large treatment group.
This, however, did not change the observational nature of the
study, nor did it inﬂuence the interpretation of the results because
the statistical analysis adjusted for the different sizes of the treat-
ment cohorts. Importantly, any observed differences in baseline
Table 3 Hierarchical,‡ multivariate epoch analysis of the follow-up change in EQ-5D tariff score in the SOHO study
Variable (reference category) Category
Change in EQ-5D score for each epoch duration
6 months 12 months 18 months 24 months 30 months 36 months
Sex (female) Male -0.005 -0.001 -0.002 0.003 -0.010 -0.009
Duration of illness (<1 year) 1 to 5 0.007 -0.005 -0.001 -0.011 -0.008 -0.004
5 to 10 -0.010 -0.019 -0.012 -0.015 -0.030* -0.028
10 to 20 -0.017 -0.025* -0.019 -0.022 -0.028* -0.017
20+ -0.054** -0.064** -0.060** -0.079** -0.074** -0.089**
Age at ﬁrst contact for treatment (<20 years) 20 to 25 0.000 0.002 0.003 -0.006 -0.009 -0.007
25 to 30 -0.017 -0.015 -0.012 -0.030** -0.018 -0.023
30 to 35 -0.010 -0.007 -0.010 -0.035* -0.010 -0.017
35+ -0.024* -0.038** -0.043** -0.050** -0.037** -0.056**
BMI (under and normal)† Obese -0.005 -0.005 -0.011 -0.012 -0.007 0.009
Overweight -0.008 0.009 -0.004 0.002 0.008 0.012
Spouse (no) Yes 0.005 0.008 0.004 0.019* 0.024** 0.008
Independent housing (no) Yes 0.002 0.003 0.003 0.013 -0.002 0.034**
Paid employment (no) Yes 0.030** 0.023** 0.011 0.014 0.026* 0.025*
Number of social activities (zero activities) 1 to 4 0.020** 0.022** 0.014* 0.013 0.007 0.016
5+ 0.021* 0.024* 0.026* 0.019* 0.012 0.012
Previous oral typical use (no) Yes -0.001 0.005 -0.008 0.008 0.005 0.006
Previous depot typical use (no) Yes 0.009 -0.007 -0.019* -0.011 0.002 -0.030*
Previous clozapine use (no) Yes -0.040* -0.064** -0.048* -0.068** -0.039 -0.047*
Previous olanzapine use (no) Yes -0.004 -0.010 -0.013 -0.005 -0.007 -0.002
Previous risperidone use (no) Yes -0.010 -0.002 -0.013 0.000 -0.001 -0.008
Previous other atypical use (no) Yes -0.014 -0.024 -0.012 -0.001 0.006 0.006
First episode (no) Yes 0.008 0.004 -0.005 -0.002 -0.010 -0.001
Anticholinergics use (no) Yes -0.004 0.010 0.001 0.024* 0.018 0.025
Antidepressant use (no) Yes -0.026** -0.033** -0.017 -0.007 -0.025 -0.027
Anxiolytics/Hypnotic use (no) Yes -0.011 -0.006 0.001 0.017 0.017 0.012
Mood stabilizer use (no) Yes -0.003 -0.004 0.004 0.003 0.005 0.004
Any concomitant (no) Yes -0.006 0.002 0.014 0.026 0.025 0.002
Positive CGI NA 0.000 -0.002 0.000 0.004 -0.002 0.008
Negative CGI NA 0.002 -0.004 -0.002 0.000 0.005 0.010*
Depressive CGI NA 0.000 0.004 0.002 0.004 0.006 0.007
Cognitive CGI NA -0.003 -0.003 -0.001 0.000 -0.003 -0.001
Overall CGI (1–2) 3 0.001 -0.003 0.008 0.011 -0.013 -0.026
4 -0.002 0.006 0.023 0.014 -0.006 -0.040*
5 -0.010 0.003 0.021 0.023 0.029 -0.019
6 to 7 -0.004 0.062 -0.004 0.046 0.132** 0.111*
EPS (no) Yes 0.007 0.000 0.001 -0.006 -0.008 -0.004
TD (no) Yes -0.021 -0.021 0.000 -0.015 -0.012 -0.018
Jail (no) Yes 0.015 0.009 0.014 0.037* 0.028 0.028
Substance abuse (no) Yes 0.017 0.005 -0.003 -0.018 0.016 0.008
Alcohol dependence (no) Yes -0.031 0.008 -0.020 -0.023 -0.041 -0.068*
Hostile (no) Yes 0.003 -0.007 -0.004 -0.014 -0.006 -0.009
Suicide attempts (no) Yes -0.024 -0.004 -0.020 -0.001 -0.012 0.018
Baseline EQ-5D score 1 quartile 0.530** 0.560** 0.570** 0.582** 0.596** 0.623**
(4 quartile base EQ-5D score) 2 quartile 0.185** 0.210** 0.202** 0.225** 0.250** 0.282**
3 quartile 0.081** 0.085** 0.085** 0.101** 0.113** 0.105**
Treatment (olanzapine) Amisulpride -0.018 -0.033 -0.026 -0.035 -0.036 -0.044
Clozapine 0.005 -0.003 0.010 0.011 0.009 0.019
Depot typical -0.064** -0.062** -0.055** -0.047** -0.043* -0.090**
Oral typical -0.077** -0.078** -0.064** -0.072** -0.070** -0.085**
Quetiapine -0.043** -0.039** -0.031* -0.045** -0.062** -0.031
Risperidone -0.032** -0.040** -0.035** -0.026** -0.030** -0.019
*P < 0.05; **P < 0.01 versus reference category.
†BMI categories: under and normal (<25 kg/m2), overweight (25–30 kg/m2), and obese (>30 kg/m2).
‡The participating investigator has been considered a random effect.
BMI, body mass index; CGI, clinical global impression; EQ-5D, EuroQol-5D; EPS, extra-pyramidal symptoms; SOHO, Schizophrenia Outpatients Health Outcomes;TD, tardive dyskinesia.
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characteristics between treatment groups were taken into
account in the multivariate analyses. Also, we interpret magni-
tude of change rather than statistical signiﬁcance. Second, selec-
tion bias might have been operating (even if involuntarily) to
maximize the beneﬁts of a particular treatment. Nevertheless,
any such selection bias has been taken into account in the mul-
tivariate, multilevel analyses performed. In addition, it is impor-
tant to emphasize that the outcome measure used (EQ-5D) was
not assessed by the clinician but was self-rated by the patient.
Finally, the main HRQL instrument used in this study, EQ-5D,
has been used in many other studies, but in few clinical trials
assessing the effectiveness of antipsychotic treatment. This makes
the results difﬁcult to compare with previous studies. Neverthe-
less, the EQ-5D is widely used in Europe [21,28], the United
States [39], and other countries [21]. Based on these data, it is
clear that the patients with schizophrenia in the SOHO study had
an impaired HRQL at study entry and that continuous treatment
was associated with an important, maintained improvement in
HRQL that approached that of the general population average.
In summary, we present data on longer term HRQL based
on a naturalistic follow-up study that has taken into account
the medication changes occurring during the 3-year observation
period. Our results show important and continued beneﬁt asso-
ciated with antipsychotic treatment in outpatients with schizo-
phrenia. The results also illustrate the need to take into account
all medication changes and other variables that associated with
a change in HRQL.
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